Breaking News, Trials & Filings

FDA Approves Emergent BioSolutions Anthrasil

Triggers $7 million BARDA milestone

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent BioSolutions, Inc. received approval from the FDA for Anthrasil  [Anthrax Immune Globulin Intravenous (Human)] for the treatment of inhalational anthrax in combination with antibacterial drugs, triggering a $7 million milestone payment under a development contract with the Biomedical Advanced Research and Development Authority (BARDA). Anthrasil also received Orphan Drug designation, qualifying for seven years of market exclusivity.   Anthrasil is a sterile solution of purified human im...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters